Released: Monday 14th November 2022

TauRx Announces Additional Investment of USD119 million following
announcement of Phase 3 LUCIDITY Topline Results

______________________________________________________________________________________________

• Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability
• Shareholder commitment to TauRx represents a significant success story for UK-based life sciences research and development in areas of great unmet medical need
• TauRx will present the Phase 3 findings at the Clinical Trials in Alzheimer’s Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco

______________________________________________________________________________________________

Aberdeen, UK and Singapore, November 14, 2022
TauRx Pharmaceuticals Ltd is a global leader in tau-based research in Alzheimer’s disease (AD).
Pathological aggregation of Tau correlates with clinical disease severity and brain atrophy. It is a
hallmark of the disease recognised as an important potential target for treating AD. HMTM is an oral
tau aggregation inhibitor, targeting this underlying pathology.

Glenn Corr, Chief Operating Officer and Chief Business Officer said: “We appreciate the
continued support of our shareholders as evidenced by their exercise of warrants. This
represents a firm commitment to our mission – ‘To discover, develop, and commercialise
innovative products for the diagnosis and treatment of neurodegenerative diseases caused
by protein aggregation’. Beyond funding regulatory submissions in the UK, US and Canada,
this investment will also advance development plans for regulatory approval in China.”

The positive outcome of this funding round, with more than 99% of warrants exercised, was
triggered by the announcement of Phase 3 LUCIDITY (NCT03446001) topline data and adds to USD64
million raised in 2021 through a previous rights issue.

TauRx, supported by its group of strategic advisors, are moving forward in the regulatory submission
process. This represents a monumental success for UK-based life sciences research and has potential
to deliver a much-needed additional treatment option for the millions of people with Alzheimer’s.

On Monday, 14 November, TauRx will present at the LSX Inv€$tival conference in London and attend
the Jefferies Healthcare conference later in the week. Results from the LUCIDITY trial will be
presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco on 30
November.

For more details please click here.